Tobias Gustavson
Senior Director, Bioconjugation & CMC VAR2 Pharmaceuticals
Senior director at VAR2 Pharmaceuticals with more than 10 years of experience in target validation, drug development and translation into clinical trials. Ph.D in Biochemistry and Associate Professor at the Copenhagen University
Seminars
Tuesday 9th March 2027
From Target to Clinic – Development & Manufacturing of the First in Class VARTUMAB ADC
- Oncofetal chondroitin sulfate, an abundant pan-cancer target present on cancer cells and in the tumor stroma
- Selection of a monovalent scFv–Fc VARTUMAB ADC format, enabling a homogeneous DAR2 construct with deep tumor penetration and potent bystander activity
- GMP manufacturing and control of VARTUMAB ADC achieving high yield, purity and stability
